333 related articles for article (PubMed ID: 19491141)
1. How willing are the public to pay for anti-hypertensive drugs for primary prevention of cardiovascular disease: a survey in a Chinese city.
Tang JL; Wang WZ; An JG; Hu YH; Cheng SH; Griffiths S
Int J Epidemiol; 2010 Feb; 39(1):244-54. PubMed ID: 19491141
[TBL] [Abstract][Full Text] [Related]
2. Gap between evidence and physicians' knowledge and practice regarding hypertension and its drug treatment: a survey in a Chinese city.
Wang WZ; Tang JL; Hu YH; An JG; Wang YL; Ren ZH; Zhang H; Griffiths S
Chin Med J (Engl); 2011 Apr; 124(8):1235-41. PubMed ID: 21543003
[TBL] [Abstract][Full Text] [Related]
3. [Cost of cardiovascular risk factor prevention in middle-aged French men. The PRIME study].
Marques-Vidal P; Arveiler D; Amouyel P; Ducimetière P; Ferrières J
Rev Epidemiol Sante Publique; 2001 Dec; 49(6):541-9. PubMed ID: 11845103
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of severe arterial hypertension: cost of drug prescriptions in accordance with ANAES guidelines].
Fender P; Guilhot J; Tilly B; Salanave B; Allemand H
Therapie; 2001; 56(2):111-8. PubMed ID: 11471361
[TBL] [Abstract][Full Text] [Related]
5. The cost-effectiveness of drug treatments for primary prevention of cardiovascular disease: a modelling study.
Marshall T
Eur J Cardiovasc Prev Rehabil; 2006 Aug; 13(4):523-8. PubMed ID: 16874140
[TBL] [Abstract][Full Text] [Related]
6. Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.
Adigun AQ; Ishola DA; Akintomide AO; Ajayi AA
J Hum Hypertens; 2003 Apr; 17(4):277-85. PubMed ID: 12714973
[TBL] [Abstract][Full Text] [Related]
7. Inertia or inaction? Blood pressure management and cardiovascular risk in diabetes.
Owen AJ; Retegan C; Rockell M; Jennings G; Reid CM
Clin Exp Pharmacol Physiol; 2009 Jul; 36(7):643-7. PubMed ID: 19076166
[TBL] [Abstract][Full Text] [Related]
8. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian city: populational study.
Moreira GC; Cipullo JP; Martin JF; Ciorlia LA; Godoy MR; Cesarino CB; Cordeiro JA; Lupino PL; Ciorlia G; Burdmann EA
J Hypertens; 2009 Sep; 27(9):1900-7. PubMed ID: 19587607
[TBL] [Abstract][Full Text] [Related]
10. Differences in need for antihypertensive drugs among those aware and unaware of their hypertensive status: a cross sectional survey.
Khan NA; Wardman D; Campbell NR
BMC Cardiovasc Disord; 2005 Feb; 5(1):4. PubMed ID: 15691376
[TBL] [Abstract][Full Text] [Related]
11. [Trends in prevalence, awareness, treatment and control of hypertension in middle-aged Chinese population].
Wang ZW; Wu YF; Zhao LC; Li Y; Yang J; Zhou BF;
Zhonghua Liu Xing Bing Xue Za Zhi; 2004 May; 25(5):407-11. PubMed ID: 15231166
[TBL] [Abstract][Full Text] [Related]
12. [Cost-effectiveness analysis on compound anti-hypertensive tablets for primary hypertension].
Wu YQ; Hu YH; Ren T; Wu T; Tao QS; Qin XY; Zhang Y; Zhan SY; Cao WH; Li LM
Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Apr; 29(4):383-6. PubMed ID: 18843999
[TBL] [Abstract][Full Text] [Related]
13. ESH-ESC guidelines for the management of hypertension.
Erdine S; Ari O; Zanchetti A; Cifkova R; Fagard R; Kjeldsen S; Mancia G; Poulter N; Rahn KH; Rodicio JL; Ruilope LM; Staessen J; van Zwieten P; Waeber B; Williams B
Herz; 2006 Jun; 31(4):331-8. PubMed ID: 16810473
[TBL] [Abstract][Full Text] [Related]
14. Commentary: The challenge of prevention in China.
McGhee SM; Hedley AJ
Int J Epidemiol; 2010 Feb; 39(1):254-5. PubMed ID: 20056766
[No Abstract] [Full Text] [Related]
15. Willingness to pay for cataract surgery in rural Southern China.
He M; Chan V; Baruwa E; Gilbert D; Frick KD; Congdon N
Ophthalmology; 2007 Mar; 114(3):411-6. PubMed ID: 17197026
[TBL] [Abstract][Full Text] [Related]
16. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
17. [Retrospective studies and prospects of therapy for hypertension].
Maisch B; Brilla C; Kruse T; Noll B; Bethge C
Herz; 1995 Dec; 20(6):370-89. PubMed ID: 8582697
[TBL] [Abstract][Full Text] [Related]
18. A general practice-based study examining the absolute risk of cardiovascular disease in treated hypertensive patients.
Fahey TP; Peters TJ
Br J Gen Pract; 1996 Nov; 46(412):655-9. PubMed ID: 8978111
[TBL] [Abstract][Full Text] [Related]
19. Modelling the potential impact of population-wide and targeted high-risk blood pressure-lowering strategies on cardiovascular disease in China.
Qin X; Jackson R; Marshall R; Lee L; Cao W; Zhan S; Hu Y
Eur J Cardiovasc Prev Rehabil; 2009 Feb; 16(1):96-101. PubMed ID: 19237999
[TBL] [Abstract][Full Text] [Related]
20. Assessing the willingness of the public to pay to conserve urban green space: the Hangzhou City, China, case.
Chen B; Bao Z; Zhu Z
J Environ Health; 2006 Dec; 69(5):26-30. PubMed ID: 17190339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
